Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne Vulgaris
Research from University of Texas yields new data on acne vulgaris
April 27th, 2008
"Two 12-week, randomized, vehicle-controlled, double-blinded pivotal studies and a 12-month, long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37%) were adolescents aged 12 to 15 years and comprised the subgroup reported here," investigators in the United States report. "Participants randomly were assigned to twice-daily treatment with dapsone gel (n = 578) or vehicle gel (n = 547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n = 181). In the...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-27)
|
